Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Ogle

Psychiatry Indianapolis, IN Medical Doctor

NPI 1801842422 CMS profile 172389

7150 Clearvista Dr, Indianapolis, IN 46256

Open in the dashboard

General payments

$5,172

327 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Ogle of Indianapolis, IN is reported in the CMS Open Payments database as having received $5,172 across 327 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $642 36
2024 General $492 34
2023 General $728 40
2022 General $848 50
2021 General $764 51
2020 General $686 50
2019 General $1,012 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Ogle
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mark Ogle were reported at $642. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mark Ogle Psychiatry median Middle half National median
2019 $1,012 $184 $59–$605 $163
2020 $686 $119 $36–$372 $114
2021 $764 $143 $43–$576 $132
2022 $848 $153 $50–$590 $149
2023 $728 $170 $56–$651 $160
2024 $492 $179 $57–$673 $164
2025 $642 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,065 74 payments
  2. Allergan Inc. $503 42 payments
  3. Janssen Pharmaceuticals, Inc $439 22 payments
  4. Otsuka America Pharmaceutical, Inc. $432 20 payments
  5. Lundbeck LLC $390 23 payments
  6. Neurocrine Biosciences, Inc. $351 21 payments
  7. ITI, Inc. $289 16 payments
  8. Vanda Pharmaceuticals Inc. $265 16 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $198 13 payments
  10. Teva Pharmaceuticals USA, Inc. $177 13 payments
  11. Other $1,063 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,125 326 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $963 69 payments
  2. VRAYLAR Neuroscience $604 47 payments
  3. REXULTI Psychiatry $417 19 payments
  4. SPRAVATO $408 20 payments
  5. HETLIOZ $265 16 payments
  6. FANAPT $265 16 payments
  7. CAPLYTA $213 12 payments
  8. INGREZZA $212 12 payments
  9. REXULTI Psychiatry $187 11 payments
  10. TRINTELLIX $160 10 payments
  11. Other $2,137 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

9,075

Median for Psychiatry: 574

Drug cost

$1,097,017

Median for Psychiatry: $27,624

Branded share of claims

19.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 44 $368,270
Caplyta Lumateperone Tosylate Brand 71 $118,916
Trintellix Vortioxetine Hydrobromide Brand 142 $103,544
Vraylar Cariprazine Hcl Brand 50 $89,605
Austedo Xr Deutetrabenazine Brand 11 $79,907
Rexulti Brexpiprazole Brand 31 $37,068
Olanzapine Generic 392 $21,927
Aripiprazole Generic 319 $20,245
Bupropion Xl Bupropion Hcl Brand 584 $16,425
Paroxetine Hcl Generic 140 $12,411

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$53,374

Medicare's payments for the services billed

Medicare patients

294

Average age 72

Services billed

1,030

177 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 69%
Arthritis 48%
Diabetes 30%
Ischemic heart disease 26%
Chronic kidney disease 26%
Alzheimer's or dementia 21%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $158
$158 50 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
  • Lundbeck LLC $52
$107 31 —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $54
$54 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $48
$48 44 —
CAPLYTA
  • ITI, Inc. $18
$18 71 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

327 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record